Obesity & liver diseases

Product Name
Preclinical
Phase 1
Phase 2
Phase 3
Status1
Preclinical
Phase 1
Phase 2
Phase 3
Pemvidutide
(ALT-801)

Obesity

55%
Status2
MOMENTUM Obesity trial top line 48-wk results in Q4 2023
Pemvidutide
(ALT-801)

NASH

55%
Status2
IMPACT Phase 2b NASH trial top line data in Q1 2025
Preclinical
Phase 1
Phase 2
Phase 3
HepTcell

Chronic HBV

55%
Status2
Top line data in Q1 2024